Q1 2024 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2024-05-15 · accession 0001493152-24-019869
$436.9M
Reported value
51
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $60.5M | 13.9% | 6,653,138 | Common | SOLE |
| 415858109 | HROW | HARROW HEALTH INC | $51.9M | 11.9% | 3,920,600 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $34.7M | 7.94% | 2,280,000 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $24.3M | 5.57% | 367,500 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $22.3M | 5.11% | 515,000 | Common | SOLE |
| 14888U101 | CPRX | CATALYST PHARMACEUTICALS INC | $16.0M | 3.66% | 1,004,355 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $13.6M | 3.12% | 330,000 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $13.3M | 3.04% | 897,000 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $12.8M | 2.93% | 435,573 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $12.1M | 2.78% | 665,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS INC | $11.0M | 2.51% | 344,123 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $10.9M | 2.49% | 3,120,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $10.8M | 2.47% | 2,692,594 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $10.7M | 2.44% | 1,580,000 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $9.2M | 2.10% | 2,445,781 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $9.1M | 2.09% | 2,645,000 | Common | SOLE |
| 55083R104 | — | LYELL IMMUNOPHARMA INC | $7.5M | 1.71% | 3,355,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $7.5M | 1.71% | 315,388 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $7.1M | 1.62% | 1,285,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $7.0M | 1.61% | 255,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $6.3M | 1.44% | 3,170,000 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $6.0M | 1.38% | 250,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $5.8M | 1.33% | 395,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $5.8M | 1.33% | 85,000 | Common | SOLE |
| B6S7WD106 | NYXH | NYXOAH S A | $4.3M | 0.99% | 320,000 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $4.3M | 0.97% | 855,000 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $4.2M | 0.96% | 787,545 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $4.0M | 0.93% | 270,000 | Common | SOLE |
| 761330109 | RVNCEUR | REVANCE THERAPEUTICS INC | $3.9M | 0.88% | 785,000 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS | $3.7M | 0.84% | 1,770,000 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $3.5M | 0.81% | 759,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $3.3M | 0.75% | 112,700 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $3.2M | 0.74% | 8,000,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $3.2M | 0.72% | 200,000 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $3.1M | 0.70% | 2,435,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $2.9M | 0.66% | 2,440,109 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $2.8M | 0.63% | 680,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $2.5M | 0.57% | 211,400 | Common | SOLE |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $1.6M | 0.37% | 1,630,000 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $1.5M | 0.35% | 1,108,357 | Common | SOLE |
| 74017N105 | PGEN | PRECIGEN INC | $1.4M | 0.31% | 947,500 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $1.3M | 0.30% | 174,413 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $1.2M | 0.28% | 130,000 | Common | SOLE |
| 617760202 | MOR2 | MORPHOSYS AG | $1.2M | 0.27% | 65,000 | Common | SOLE |
| 377322102 | GKOS | GLAUKOS CORP | $808,631 | 0.19% | 8,576 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $802,130 | 0.18% | 471,481 | Common | SOLE |
| 09075X108 | — | BIODESIX | $764,560 | 0.17% | 534,657 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $490,487 | 0.11% | 170,308 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $455,543 | 0.10% | 113,038 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS iNC | $318,212 | 0.07% | 67,561 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS INC | $210,000 | 0.05% | 210,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.